MedTrace Logo

Effects of CB1 Antagonist/Reverse Agonist Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury

NCT05622994 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2022-11-21

No results posted yet for this study

Summary

This is a placebo controlled study comparing Rimonabant 5 mg per day for 90 days with placebo for the same period. Objective is to improve walking abilities of spinal cord injury individuals (incomplete lesions) and demonstrate that it is a safe treatment in spinal cord injury population.

Conditions

  • Spinal Cord Injuries

Interventions

DRUG

Rimonabant

Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.

Sponsors & Collaborators

  • Hospital Nacional de Parapléjicos de Toledo

    lead OTHER

Principal Investigators

  • Antonio Oliviero, MD, PhD · Hospital Nacional de Parapléjicos

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-30
Primary Completion
2023-11-30
Completion
2023-11-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05622994 on ClinicalTrials.gov